Developer docs
API playgroundTry for free, no card

Search company profiles

PATH

Full company profile

uuid002jjo6

Namestring
PATH
Legal namestring
PATH Decision Support Software LLC
Websiteurl
glucosepath.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

PATH Decision Support Software LLC, operating under the trade names GlucosePATH and PATH, is a privately held US company headquartered in Celebration, Florida. The company develops a clinical decision support platform that helps licensed healthcare providers and Type 2 Diabetes patients select personalized medication regimens. The product addresses the combinatorial complexity of Type 2 Diabetes pharmacotherapy — more than 60 FDA-approved medications yielding nearly 6 million possible combination regimens — by evaluating each regimen against five criteria: A1c reduction, cost, weight change, side effects, and likely adherence. Distribution is restricted to US-licensed healthcare professionals who register at glucosepath.com with NPI verification, and the company explicitly serves only Users located within the United States.

The core technology is a combinatorial optimization engine that ingests standardized clinical inputs from FDA labels, peer-reviewed literature, insurance formularies, manufacturer coupons, and patient-specific data (HbA1c level, medical history, insurance coverage, monthly budget, and adherence barriers). The engine produces up to 10 treatment options per patient, each scored from 0 to 100 with quantified trade-offs across price points and clinical outcomes, enabling a shared decision-making workflow between provider and patient. Formulary and benefits data integration is enabled through a strategic co-development partnership with Vericred. Documented outcomes include a 1.5% average HbA1c reduction at 90 days for full-adherence patients, $764 estimated annual out-of-pocket savings per patient, and over $1.1 million in potential annual prescription savings for a self-insured employer covering approximately 600 Type 2 Diabetes employees.

The company is currently in a pre-release evaluation phase. No commercial product is sold, no pricing tiers are publicly disclosed, and no revenue is generated. The intended revenue model is a recurring subscription aimed primarily at healthcare providers, with secondary monetization potential directed at insurers, employers, and hospital systems based on published case studies. The company has built clinical credibility through presentations at the American Diabetes Association (2017, 2018) and the American Association of Clinical Endocrinologists (2016), and won a first-place poster award at AACE 2016. No funding rounds, management team, patents, or regulatory clearances are disclosed in the source material, and the LLC appears to be founder-owned and operated.

Short descriptiontext

PATH Decision Support Software LLC operates GlucosePATH, a US clinical decision support platform that helps licensed healthcare providers and Type 2 Diabetes patients evaluate nearly 6 million medication combinations across efficacy, cost, side effects, weight change, and adherence, producing personalized 0-to-100 scored treatment recommendations.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersOrlando, United States
HQ citystring
Orlando
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical decision support, diabetes treatment software, medication regimen optimization, healthcare decision support, shared decision making
Industry3 codes
1Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD)
CodeHLACAGAGPrimaryYes
2Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
CodeHLAHAHAJPrimaryNo
3PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools)
CodeHLAEAKALPrimaryNo
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Decision Support Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-release Evaluation
TypeSubscription Recurring
Description

PATH is not currently available as a commercial product; it is available for pre-release evaluation only. No active revenue generation.

glucosepath.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

PATH Decision Support Software LLC develops GlucosePATH, a clinical decision support software platform that evaluates nearly 6 million possible medication combinations for Type 2 Diabetes patients using five criteria: A1c Reduction, Cost, Weight Change, Side Effects, and Likely Adherence. The software uses FDA label data, peer-reviewed research, insurance formulary information, and patient budget preferences to generate personalized treatment recommendations scored 0-100, enabling shared decision-making between licensed healthcare providers and patients. The platform is currently available for pre-release evaluation only, not as a commercial product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1.5% average HbA1c reduction after 90 days (full adherence to recommendations)
+3 more records
Product overview1 text field

PATH Decision Support Software LLC offers GlucosePATH as a single unified clinical decision support product. The platform evaluates over 60 FDA-approved Type 2 Diabetes treatments, considering nearly 6 million possible medication combinations, to generate personalized recommendations scored from 0-100. It integrates patient data, insurance coverage, budget constraints, and clinical outcomes to support shared decision-making between providers and patients.

Product and service1 record
1GlucosePATH
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Vericred
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Len Testa and Vericred team collaborated to launch GlucosePATH. Vericred provides expertise in insurance and benefits technology, likely contributing formulary and coverage data integration capabilities.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PATH

Clinical Decision Support Softwareglucosepath.com

PATH Decision Support Software LLC operates GlucosePATH, a US clinical decision support platform that helps licensed healthcare providers and Type 2 Diabetes patients evaluate nearly 6 million medication combinations across efficacy, cost, side effects, weight change, and adherence, producing personalized 0-to-100 scored treatment recommendations.

What PATH does

PATH Decision Support Software LLC, operating under the trade names GlucosePATH and PATH, is a privately held US company headquartered in Celebration, Florida. The company develops a clinical decision support platform that helps licensed healthcare providers and Type 2 Diabetes patients select personalized medication regimens. The product addresses the combinatorial complexity of Type 2 Diabetes pharmacotherapy — more than 60 FDA-approved medications yielding nearly 6 million possible combination regimens — by evaluating each regimen against five criteria: A1c reduction, cost, weight change, side effects, and likely adherence. Distribution is restricted to US-licensed healthcare professionals who register at glucosepath.com with NPI verification, and the company explicitly serves only Users located within the United States.

The core technology is a combinatorial optimization engine that ingests standardized clinical inputs from FDA labels, peer-reviewed literature, insurance formularies, manufacturer coupons, and patient-specific data (HbA1c level, medical history, insurance coverage, monthly budget, and adherence barriers). The engine produces up to 10 treatment options per patient, each scored from 0 to 100 with quantified trade-offs across price points and clinical outcomes, enabling a shared decision-making workflow between provider and patient. Formulary and benefits data integration is enabled through a strategic co-development partnership with Vericred. Documented outcomes include a 1.5% average HbA1c reduction at 90 days for full-adherence patients, $764 estimated annual out-of-pocket savings per patient, and over $1.1 million in potential annual prescription savings for a self-insured employer covering approximately 600 Type 2 Diabetes employees.

The company is currently in a pre-release evaluation phase. No commercial product is sold, no pricing tiers are publicly disclosed, and no revenue is generated. The intended revenue model is a recurring subscription aimed primarily at healthcare providers, with secondary monetization potential directed at insurers, employers, and hospital systems based on published case studies. The company has built clinical credibility through presentations at the American Diabetes Association (2017, 2018) and the American Association of Clinical Endocrinologists (2016), and won a first-place poster award at AACE 2016. No funding rounds, management team, patents, or regulatory clearances are disclosed in the source material, and the LLC appears to be founder-owned and operated.

PATH firmographics

Firmographics
Name
PATH
Legal name
PATH Decision Support Software LLC
Website
https://glucosepath.com
Company type
Private
Operating status
Operating
Short description
PATH Decision Support Software LLC operates GlucosePATH, a US clinical decision support platform that helps licensed healthcare providers and Type 2 Diabetes patients evaluate nearly 6 million medication combinations across efficacy, cost, side effects, weight change, and adherence, producing personalized 0-to-100 scored treatment recommendations.
Ownership category
akta.pro rank

PATH industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro primary industry
Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)
akta.pro secondary industries
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), PBM Technology Platforms (ePA/eRx/Real-Time Benefit Tools) (HLAEAKAL)

Keywords

  • Clinical decision support
  • Diabetes treatment software
  • Medication regimen optimization
  • Healthcare decision support
  • Shared decision making

Where PATH is headquartered

Location

Headquarters

HQ city
Orlando
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PATH business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Pre-release Evaluation: PATH is not currently available as a commercial product; it is available for pre-release evaluation only. No active revenue generation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

PATH product offering

Product offering

Core offering

PATH Decision Support Software LLC develops GlucosePATH, a clinical decision support software platform that evaluates nearly 6 million possible medication combinations for Type 2 Diabetes patients using five criteria: A1c Reduction, Cost, Weight Change, Side Effects, and Likely Adherence. The software uses FDA label data, peer-reviewed research, insurance formulary information, and patient budget preferences to generate personalized treatment recommendations scored 0-100, enabling shared decision-making between licensed healthcare providers and patients. The platform is currently available for pre-release evaluation only, not as a commercial product.

Product overview

PATH Decision Support Software LLC offers GlucosePATH as a single unified clinical decision support product. The platform evaluates over 60 FDA-approved Type 2 Diabetes treatments, considering nearly 6 million possible medication combinations, to generate personalized recommendations scored from 0-100. It integrates patient data, insurance coverage, budget constraints, and clinical outcomes to support shared decision-making between providers and patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • GlucosePATH

Quantifiable outcome

  • 1.5% average HbA1c reduction after 90 days (full adherence to recommendations)
  • +3 more outcomes

Companies that use PATH

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

PATH technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

PATH partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • VericredminorStrategic or Co-development PartnerLen Testa and Vericred team collaborated to launch GlucosePATH. Vericred provides expertise in insurance and benefits technology, likely contributing formulary and coverage data integration capabilities.

Scale indicators6 records

Recent moves4 records

Expansion highlights4 records

PATH competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

PATH social profiles

Digital presence

PATH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PATH leadership team

Management profile

Number of profiles

PATH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PATH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PATH

What does PATH do?

PATH Decision Support Software LLC develops GlucosePATH, a clinical decision support software platform that evaluates nearly 6 million possible medication combinations for Type 2 Diabetes patients using five criteria: A1c Reduction, Cost, Weight Change, Side Effects, and Likely Adherence. The software uses FDA label data, peer-reviewed research, insurance formulary information, and patient budget preferences to generate personalized treatment recommendations scored 0-100, enabling shared decision-making between licensed healthcare providers and patients. The platform is currently available for pre-release evaluation only, not as a commercial product.

Is PATH a public or private company?

PATH is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PATH founded?

PATH was founded in -1.

Where is PATH based?

PATH is headquartered in Orlando, United States, in the North America region.

How does PATH make money?

One revenue line is on record: pre-release Evaluation.

Does PATH have an API?

No public API is recorded for PATH.

What industry is PATH in?

PATH's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAG, Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD), with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales